European Patent Office intends to grant patent for Intezyne's IVECT Method

Intezyne today announced it has received notification the European Patent Office intends to grant a patent covering a key element of Intezyne's breakthrough drug delivery technology, the IVECT™ Method. At the core of this technology is the IVECT micelle, a proprietary, polymeric nanoparticle designed to encapsulate and deliver best-in-class therapeutics, while limiting exposure to healthy tissues. The IVECT Method is already covered by seven additional patents both in the United States and worldwide. This wide-ranging, European patent covers technology that allows greater flexibility and versatility of the IVECT micelle, particularly with respect to the amount of hydrophobic material that can be encapsulated into this drug delivery vehicle, further bolstering Intezyne's intellectual property portfolio.

“Historically, encapsulating highly hydrophobic drugs has proven to be a major stumbling block for the great majority of drug delivery systems”

"Historically, encapsulating highly hydrophobic drugs has proven to be a major stumbling block for the great majority of drug delivery systems," explained Kevin Sill, Ph.D., Chief Scientific Officer of Intezyne. "The advanced technology covered by this patent protects Intezyne's ability to encapsulate hydrophobic drugs more efficiently. Further, we have shown for the first time IVECT micelles are able to encapsulate several hydrophobic compounds that were previously intractable to delivery methods at therapeutically relevant levels."

Intezyne is active in its efforts to prosecute its patents and protect its intellectual property in major global pharmaceutical markets. The above patent currently is being prosecuted in the United States, as well as Australia, Canada, Israel, India, Japan, Mexico, and New Zealand.

All granted and pending patent applications are wholly owned by Intezyne.

SOURCE Intezyne